LIFE SCIENCES + HEALTHCARE + MEDICAL DEVICES
CEO ELEVATOR PITCH OLYMPICS 12Nov’12
hosted by www.VANJ.com at the Whippany Marriott
Entrepreneurs Make their Two-Minute Pitch
Panel of Judges BioCapital Fund Managers
Scored Competition, during lunch 12n –to- 3p
Entrepreneurs’ Booths & Posters: Exhibit Hall Open 10-12n, and 3-4p
WINNING CEOs Will Go On to Meet One-On-One
w/ BioCapital VCs, in Reverse Venture Fair format – to 4:30p.
Our Judges are being joined by Sponsors, Angels, & thirty (30) qualified CEOs:
Rajeev Dadoo, PhD, Partner, SR One GlaxoSmithKline’s VC arm
Brenda Gavin, DVM, Founding Partner Quaker BioVentures
Noah J. Kroloff, Partner, NGN Capital
John Clarke, Founding Partner, Cardinal Partners
Zev Sherl, Partner NewSpring Capital
Debbie Hart, President, BioNJ
Martin Kratchman, Founding Partner HealthPro BioVentures
Rajeev Dadoo, PhD, Partner, SR One serves as Director on Boards of NeuroThera-peutics Pharma and Synovex and Observer on Ipierian and Concert Pharma, and involved w/ investments in Cydex, Hypnion, Predix Pharma, Rib-X Pharma, Octoplus, Trigen, Nucleonics, & Pinnacle Pharma. Prior, Rajeev worked in Genentech’s technology & clinical development Bio-Rad Laboratories’ product development, plus bus dev at Genome Therapeutics. Rajeev co-founded Unimicro Tech to commercialize instrumentation for biomedical analysis.
SR One GlaxoSmithKline’s VC arm invests globally in early stage healthcare firms pursuing innovative, break-through science+ access technology innovations from GSK creating new value using inventions for products in other industries that can provide attractive financial returns plus significant strategic value: in life science sectors, prefer to lead / co-lead investment. We actively syndicate and align w/ other financial investors, & do not ask for specific product rights or options. We are active investors and typically take board of directors or board observer seats. We maintain a strict firewall with GSK on confidential items received from a portfolio co or investment opportunities under review.
Brenda Gavin, DVM, Founding Partner, Quaker BioVentures Prev. President, S.R. One, VC arm of GlaxoSmithKline. And GP, EuclidSR Partners, an independent VC fund focused on healthcare and info tech. While at SROne Dr. Gavin was responsible for dozens of venture + strategic investments, serving as a board member or active board observer for many portfolio companies.
Quaker Partners invests $5.0M to $25.0M in each Co. preferring to lead or co-lead investments w/ active board involvement, seeking to deliver superior financial returns by investing in healthcare co.s that develop innovative and cost effective medical solutions across all sectors of: pharma, biotech, healthcare services, and medical devices – tools & human diagnostics, and diversifies by investing in healthcare companies at various stages of development, from start-ups to companies that are marketing products and services.
Noah J. Kroloff, Partner, NGN Capital Prior to VC, had many Sr operating roles: VP Sales & Marketing of i-STAT Corp med devices sold to Abbott Labs for $450.M, led global alliance w/ Abbott + $61.M alliance with HP Med Products. Prior, he was an Engagement Manager at McKinsey & Co. advising leading pharma and diagnostic CEOs on R&D mgmt, portfolio strategy, & alliance formation. He’s BoD: BeneChill, Valtech Cardio, and Coagulation Sciences, Observer of Cerapedics, Inc. Member of McKinsey’s alumni advisory council and Technion NY Metro.
NGN Capital is a global healthcare VC investment fund with offices in NYC, Greenwich CT, and Heidelberg Germany, with capabilities across broad spectrum of healthcare segments including drug products, medical devices and healthcare services, with an emphasis on later-stage opportunities. In 2005 NGN closed its first healthcare fund of $250M and is now investing from its second fund: NGN BioMed Opportunity II.
NGN’s professionals were directly involved in transformational developments in healthcare that led to significant realizations for investors. NGN’s advisors are recognized experts in their respective fields of healthcare, science and corporate value creation and work actively with NGN’s professionals.
Debbie Hart, President, BioNJ works alongside NJ’s biotech leaders to promote business and public policy environments in NJ, WDC and beyond advancing growth and prosperity of NJ biotech companies. She currently serves on many advisory boards for academic, government, and industry and has earned many awards.
BioNJ accomplishes its mission through excellence ● Ensuring acquisition and availability of appropriate human capital, BioCapital, plus resources necessary to build successful biotech products and biotech support companies in NJ; ● Formulating and advocating policy positions to elected officials, regulators, the media and general public; ● Enhancing global awareness appreciation of NJ’s talents, experiences, and resources.
John Clarke, Partner, co-founded Cardinal Partners in 1997 after entering VC industry with DSV Partners in 1982. He served as interim CEO of numerous successful companies incl: Alkermes
(NASDAQ:ALKS), Arris Pharma, DNX,
Cubist Pharma (NASDAQ:CBST). He currently serves on BoD of Alnylam Pharma, (NASDAQ:ALNY), aTyr Pharma, Momenta Pharma, (NASDAQ:MNTA), Rib-X Pharma, and Verastem . He also served as BoD for Sirtris Pharma (acquired by GSK), TechRx (Acquired by NDCHealth), Visicu (acquired by Phillips Electronics).
John is also a Trustee of Hands Together, a non-profit organization that provides health care and education support to the needy in Haiti. Prior to his VC career, he worked for GE in various sales / marketing positions.
John received his A.B. in Economics and Biology from Harvard Univ. and his MBA Wharton School at Univ. of Pennsylvania.
Cardinal Partners invests $6.-to $12.M / company. Our criterion for new projects incl: Large or fast growing available markets, Strong CEO, founder, team or scientist, Proprietary intellectual assets or novel tech-nology and a well-defined business model; in early stage companies across the spectrum of the healthcare economy. Life Sciences: since 1980s we are especially interested in novel platform technologies which will be extensible across a range of the therapeutic applications and disciplines. Many of our companies are able to fund growth very early in their development via partnerships with large pharmaceutical companies. We are frequently company co-founders, forming new entities around promising science or research. Medical Devices: products and instruments, characterized by: strong cost-benefit propositions; large unmet market opportunities; and breakthrough innovative technology. Healthcare IT: goal is to fund innovative technology / service co.s which Automate broken processes of Healthcare redefine / enhance clinical processes automate revenue-cycle challenges, enhance communication between providers payers and patients, and expedite the ongoing transition towards consumerism in healthcare.
Zev S. Sherl, Partner NewSpring Capital focused exclusively in health care + life sci industries. Prior to joining NewSpring 2003 he worked w/ Pequot Ventures managing $1.B Prior, healthcare investor team at Behrman Capital PE managing $700M. Prior to PE in 1997, Sr Dir, Strategic Plan-ning Value Health, largest independent pharmacy and mental health benefit mgmt co. led to successful sale to Columbia HCA He was also US Manager Pricing Policy at Merck, prior he was InvBanker at Lehman Bros. Zev currently on BoD: Core Essence Orthopaedics, EKR Therapeutics, Immune Control, Nitric BioTherapeutic. Frmly BoD for AppTec Lab Services prior to sale to Wuxi Pharma, and Scandius BioMedical prior to its sale to Covidien. He received a BA honors in economics Duke Univ. and MBA from Harvard Business School.
NewSpring Capital has $800 million across 3 distinct investment strategies through its family of funds:
NewSpring Growth equity capital to grow and expand companies with a focus on business services, enabling technologies, and information technology.
NewSpring Healthcare equity capital to healthcare companies within specialty pharma, healthcare services, and medical devices.
NewSpring Mezzanine capital for expansion stage and buy out opportunities in business services, health care, info tech, and specialty manufacturing. Principals leverage their previous experience managing and advising growth companies actually work with the senior management teams of each portfolio company to build and enhance value via: ● Strategic guidance ● Corporate governance best practices ● Building out management teams (network of executives and recruiters) ●Client and partner introductions ●Merger and acquisition advice ● Relationships with additional equity and debt capital sources ● Creating and evaluating exit opportunities
Martin Kratchman, Founding Manager HealthPro BioVentures provides a vast array of advisory and banking services to Healthcare & LifeSci: Capital Formation, M&A, Strategic Licensing and Partnering. He acts as Advisor & InvBank both public & private: financial offerings, pipeline enhancement / divestment, business dev. / corp restructuring. Specialty in healthcare since 1992 via Paramount BioCapital M&A Team: Cardiome Pharm acquisition of Paralex, Inc. and Adherex’s acquisition of Oxiquant. He raised capital for Aries Fund, did risk mgmt at Chase, derivatives at First Boston, and arbitrage at CitiCorp.
HealthPro works with Clients to ● Develop strategic goals and target lists of potential investors / buyers or sellers / partners licensors and licensees, ● Assist with presentations and due diligence dossiers ● Arrange well-vetted meetings with investors / target companies / strategic partners ● Advise on the structure, timing and pricing of the transaction terms ● Negotiate, document and close the transaction. HealthPro has developed close relationships with institutional healthcare funds and strategic investors that look to us for innovative investment opportunities. Whether we pursue a financial or strategic investment, we will access our broad network of private equity, venture capital and high net-worth investors to meet our clients financial needs.
Already one dozen Entrepreneurs are securing slots, only 20 slots available !
ELEVATOR PITCH OLYMPICS see prev. video clips.
Host: Venture Association of New Jersey, Inc. www.VANJ.com
Date & Time: Mon Nov. 12th 9:00-5:00 Venue Whippany Marriott
Register and pay VANJ $600. Earlybird by Oct 5th : $350.
Register via Exhibitor Form from: Clara Stricchiola: Clara@VANJ.com or
Dan Conley, NJAngels Life Science Investors: AngelsForums@gmail.com
CO-Producer of the Elevator Pitch Olympics is the
Entrepreneurs University programs www.e-Univ.org
Entrepreneurs Prepare By Practicing their Fast Pitch $40. / person, 4-6p at the
Commercialization Center for Innovative Technologies
#675 Route 1s, North Brunswick, NJ 08902 (GPS use #681)
Sept 13th HOW TO Procure Angel Capital: Tips, Tactics, Techniques
Oct. 2nd HOW TO Procure Venture Capital: Tips, Tactics, Techniques
Nov 6th Funded CEOs; Advice from Next Rungs Up The VC Food Chain
Dec 4th BEST of BEST CEOs for 2012: BAKE OFF FOR THE MONEY.
www.EntreUniv.org ENTREPRENEURS PREPARE TO WIN INTEREST of BioVC INVESTORS BY BECOMING READY TO PASS DUE DILIGENCE & SHOW ABILITY TO ACCEPT THE VC’s CASH.
Entrepreneurs University program format:
4:00p Venture Community announcements; capital access opportunities.
4:10p Participants Make Their One-Minute Introduction. Plus Sponsors Soapbox
4:30p CEOs Make Their FAST PITCH VENTURE PLAN PRESENTATION + Q&A
5:00p Technical Topic on: HOW TO VENTURE interactive Q&A case-by-case – above
6:00p Programs wrap, networking to 7:00p Major Sponsor: NJAngels.net 732.873.1955
ANGELS + VCs for Lunch
By Helping Entrepreneurial CEOs Organize Their
Unfair Commercial & Technological Advantages into
a Fundable Business Plan based on Know-How with:
NanoBio Tools, Materials, + Devices
Companion Diagnostics for Personalized Medicines,
Vaccines, Regen+NeuroMedicine Discovery Tools,
Drug Delivery, Patient Adherence & Compliance,
Anything for Wounded Warriors, First Responders
Dx & Tx imaging niches, InfoTech to Fix Healthcare.
COMMERCIALIZATION CENTER FOR INNOVATIVE TECHNOLOGIES
# 675 Rte 1s, No. Brunswick, NJ 08902 GPS use #681.
Angels + Presenters pre-register: AngelsForums@gmail.com
ANGELS + VCs LUNCH 10-2p $40.
10Jan’13 and then First Tuesdays through to 4June’13 Best of Best CEOs
CEO Fast Pitch Coaching: A 20-Minute Forum to Learn How CEOs Can Make
Cogent Their Company’s Venture Plan Presentation In 5-Minutes 2-4p $40. .
ENTREPRENEURS UNIVERSITY 4-6p $40 to NJEF, Inc
Technical Programs (below) Teach CEOs: HOW TO VENTURE
Sept 13th : How to Procure Angel Capital; Tools, Techniques, Tactics you can use
Oct 2nd : How to Procure Venture Capital; Tools, Techniques, Tactics you can use
Nov 6th : Funded CEOs; Valuable Advice to Get to Your Next Rung UP the VC Food Chain.
Dec 4th 2012: BEST of BEST CEOs BAKE-OFF, FOR THE MONEY
DAN CONLEY w.732.873.1955
OnCallCFO for Fundable Teams;
Managing Director NJ Angels Networks, Sponsors of
Entrepreneurs University programs: www.EntreUniv.org